Pharma Pulse 4/4/25: The ‘Healthy Immigrant Effect’, Google Gemini, AI Commercialization in Pharma & more

Google Gemini, AI Commercialization in Pharma and More

Google recently released an updated version of its AI LLM. Gemini 2.5 Pro boasts a variety of new features that could help integrate AI even more into various workflows. It is still a tool, however, and in order to get the best results, it must be used properly. EVERSANA’s SVP of innovation Abid Rahman spoke with Pharmaceutical Executive about this updated LLM and how it can be incorporated into certain aspects of pharma.

The ‘Healthy Immigrant Effect’ Is Alive and Well in Kidney Disease, Study Finds

Previous research has found that immigrants have lower rates of heart disease, diabetes, dementia and other chronic health conditions compared with nonimmigrants. A new study adds kidney disease to the list.

Pharma’s Tariff Reprieve Will Be Temporary as More Levies Loom

The drug industry won a reprieve from sweeping tariffs announced by President Donald Trump on Wednesday, though it could be short-lived as the White House moves forward with plans for future levies on pharmaceutical imports.

Unlearn and remynd Partner on Alzheimer’s Study to Strengthen Confidence in Early Clinical Signals Using Digital Twins

Unlearn has announced results from a collaboration with remynd. The results were shared at the 2025 Alzheimer’s & Parkinson’s Drug Development Summit in Boston. The collaboration focused on remynd’s Phase IIa clinical trial of REM127, an investigational, first-generation small molecule therapy targeting septins in patients with mild-to-moderate Alzheimer’s Disease (AD). The study enrolled a limited number of participants and measured changes in AD biomarkers over a short treatment window.

Alyssa Hopkins on LinkedIn

GLP-1s are booming but affordability remains a major setback.

In his interview with Pharmaceutical Commerce, Dr.Colin Banas at DrFirst, Inc. breaks down why prices are steep even with insurance and how step therapy and coverage limitations create barriers for patients.

Check out Nicholas Saraceno's latest!

https://lnkd.in/g3WHQq6G

Have news you want us to share in Pharma Pulse? Reach out to Editor Miranda Schmalfuhs